Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.
about
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimodp38 MAPK in cardioprotection - are we there yet?Finding needles in a haystack: application of network analysis and target enrichment studies for the identification of potential anti-diabetic phytochemicalsThe Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisCCAAT/enhancer-binding protein-α suppresses lung tumor development in mice through the p38α MAP kinase pathway.A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis.Role of p38 mitogen-activated protein kinase in vascular endothelial aging: interaction with Arginase-II and S6K1 signaling pathwayp38 mitogen-activated protein kinase is involved in arginase-II-mediated eNOS-uncoupling in obesityTissue-specific up-regulation of arginase I and II induced by p38 MAPK mediates endothelial dysfunction in type 1 diabetes mellitus.Altered MAPK signaling in progressive deterioration of endothelial function in diabetic mice.Arginine de novo and nitric oxide production in disease states.Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathwayArginase: the emerging therapeutic target for vascular oxidative stress and inflammation.Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.p38 MAPK Inhibition Improves Synaptic Plasticity and Memory in Angiotensin II-dependent Hypertensive Micep38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease.P38 plays an important role in glucolipotoxicity-induced apoptosis in INS-1 cells.RRM2B-Mediated Regulation of Mitochondrial Activity and Inflammation under Oxidative Stress.Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.LATITUDE-TIMI: is there still hope for anti-inflammatory therapy in acute myocardial infaction?Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod.Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell propertiesNovel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity.Losmapimod does not reduce cardiovascular events in patients with acute myocardial infarction.Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.Chronic p38 mitogen-activated protein kinase inhibition improves vascular function and remodeling in angiotensin II-dependent hypertension.SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1.The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.MicroRNA interactome analysis predicts post-transcriptional regulation of ADRB2 and PPP3R1 in the hypercholesterolemic myocardium.
P2860
Q26798359-00EB210B-CA4F-4C1D-B996-9E9B0B6A9700Q27001653-10F25DB2-EDC3-4709-90EA-960344B79FF9Q28544976-CEA601B6-2AB6-4EBA-B1EA-810767F848C2Q33838927-964D22DB-57D7-41B5-930A-A64D7B8466F9Q34599904-3BA14953-9188-4DA6-A7E1-86FCA7C6A176Q34881784-BC3F1D9D-FB66-46DE-9186-04491F32EFBBQ35149545-0EC1B5E1-B650-4A71-B6C2-1272928F7B76Q35576389-C5BD8778-67BA-428F-87E1-D314264FC7D9Q36124220-1FABC16E-2BEA-4623-9D3D-ECC70FDCAC77Q36410687-8D8CCDFB-C2F6-4302-AC12-47EF9AA04EADQ36454194-6AA731BA-B5F9-4CC5-BB2D-59F04A88F108Q36620184-80794087-5F3F-4E92-A2A4-0797940DA9DBQ36920831-5C5A0647-DA94-439B-A9F2-9B273F4D11A5Q36988007-89ECC27E-4473-4A02-95FF-B97CAAA13AEAQ36990783-C2D5B496-3D8F-4B23-B73F-268CD48E399FQ37988188-0D46D469-17C3-4110-91A3-8BC96CC30F20Q38185979-FA610161-027D-435E-8A79-E84AA0CA1198Q38482120-EF8268DA-BE66-4B73-8019-AD17A121FBBDQ38862308-A7C36006-BBF4-4618-B328-851AC9D77C02Q38995223-16433B60-5D97-445F-A1DD-E38BF966D013Q41428927-1A51BF7C-BCB0-4924-BAE3-9820C030EB6EQ41543188-D32ABA38-C90A-48CC-A857-D46A01D1DC1FQ42078200-24588DF6-E53D-4868-B089-7D84D7392CE0Q42380665-8672568B-0230-452A-9365-5BBAE5279875Q42384664-D5633422-A930-4D9C-B135-FEBE328EFCA8Q43547673-56BB2DB0-86F8-491C-ABCB-58266A94BDD4Q44613025-540E35A8-D9A7-475D-87FE-EE8BC0311547Q46013425-CA27DA0E-1FC2-48B4-9642-2A8C156FFC9FQ51645576-D8F0205D-080A-4754-840E-C81022D202C6Q54978312-275E5DB0-6EA1-4AE9-A908-0409C4A3F90BQ54981842-51429D2E-3205-4596-9C1D-FD1A85FF9DA7Q55640008-B947DBC3-B42C-4C94-86F9-12629FA9BA98
P2860
Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Inhibition of p38 mitogen-acti ...... ation in hypercholesterolemia.
@en
Inhibition of p38 mitogen-acti ...... ation in hypercholesterolemia.
@nl
type
label
Inhibition of p38 mitogen-acti ...... ation in hypercholesterolemia.
@en
Inhibition of p38 mitogen-acti ...... ation in hypercholesterolemia.
@nl
prefLabel
Inhibition of p38 mitogen-acti ...... ation in hypercholesterolemia.
@en
Inhibition of p38 mitogen-acti ...... ation in hypercholesterolemia.
@nl
P2093
P921
P1433
P1476
Inhibition of p38 mitogen-acti ...... ation in hypercholesterolemia.
@en
P2093
Andrew J Webb
David J Collier
Dennis L Sprecher
Ian B Wilkinson
John J Lepore
John Morgan
John R Cockcroft
Kaisa M Mäki-Petäjä
Lea Sarov-Blat
Maysoon Elkhawad
P304
P356
10.1161/CIRCULATIONAHA.110.971986
P407
P577
2011-01-24T00:00:00Z